Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study

Luigi Francesco Iannone,Marina Romozzi,Antonio Russo,Gennaro Saporito,Federico De Santis,Raffaele Ornello,Grazia Sances,Gloria Vaghi,Cristina Tassorelli,Maria Albanese,Simona Guerzoni,Alfonsina Casalena,Catello Vollono,Paolo Calabresi,Maria Pia Prudenzano,Edoardo Mampreso,Giorgio Dalla Volta,Maria Rosaria Valente,Gianluca Avino,Alberto Chiarugi,Simona Sacco,Francesca Pistoia,Italian Headache Registry (RICe) study group,Francesca Boscain,Roberta Bovenzi,Marco Bolchini,Matteo Cortinovis,Roberto De Icco,Natascia Ghiotto,Flavia Lo Castro,Andrea Burgalassi,Giulia Vigani,Francesco De Cesaris,Nicola Biagio Mercuri,Viviana Nociti

DOI: https://doi.org/10.1111/ene.16450

Abstract:Background and purpose: Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP mAbs) in combination with traditional drugs, scarce data are available on the safety of their combination with other mAbs. This study aimed to evaluate the 6-month effectiveness and tolerability of anti-CGRP mAbs in combination with other mAbs for different diseases. Methods: Patients included in the Italian Headache Registry and treated concomitantly with an anti-CGRP mAb and another mAb were included. Effectiveness outcomes for migraine included reduction from baseline of monthly headache days (MHDs), Migraine Disability Assessment (MIDAS) score, Headache Impact Test-6 (HIT-6) scores, and Patients' Global Impression of Change (PGIC) scale. Adverse events (AEs) were recorded. Results: Thirty-eight patients were included. In 27 patients (71.1%), the anti-CGRP mAb was added to a previously ongoing mAb. Nine patients (23.7%) discontinued one of the two mAbs before the end of treatment (seven discontinued the anti-CGRP mAb and two the other mAb). One patient discontinued for AEs. Anti-CGRP mAbs were discontinued due to ineffectiveness (n = 5, 55.5%) and one each (11.1%) for clinical remission and lost to follow-up. MHDs significantly decreased from baseline to 3 months (p < 0.0001) and 6 months (p < 0.001), as did the MIDAS and the HIT-6 scores at 3 and 6 months (p < 0.001). For anti-CGRP mAbs, 27.4% of patients reported PGIC ≥ 5 at 3 months and 48.3% at 6 months. Mild AEs associated with introduction of a second mAb were detected in six patients (15.8%). Conclusions: In this real-world study, anti-CGRP mAbs showed safety and effectiveness when administered concomitantly with other mAbs.